Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 124


Effects of Acute GLP-1 Infusion on Pulmonary and Systemic Hemodynamics in Patients With Heart Failure: A Pilot Study.

Clarke SJ, Pettit S, Giblett JP, Zhao T, Kydd AC, Albrechtsen NJW, Deacon CF, Parameshwar J, Hoole SP.

Clin Ther. 2019 Jan;41(1):118-127.e0. doi: 10.1016/j.clinthera.2018.11.013. Epub 2018 Dec 28.


The acute effects of dietary carbohydrate reduction on postprandial responses of non-esterified fatty acids and triglycerides: a randomized trial.

Samkani A, Skytte MJ, Anholm C, Astrup A, Deacon CF, Holst JJ, Madsbad S, Boston R, Krarup T, Haugaard SB.

Lipids Health Dis. 2018 Dec 27;17(1):295. doi: 10.1186/s12944-018-0953-8.


GLP-1 Is a Coronary Artery Vasodilator in Humans.

Clarke SJ, Giblett JP, Yang LL, Hubsch A, Zhao T, Aetesam-Ur-Rahman M, West NEJ, O'Sullivan M, Figg N, Bennett M, Wewer Albrechtsen NJ, Deacon CF, Cheriyan J, Hoole SP.

J Am Heart Assoc. 2018 Nov 20;7(22):e010321. doi: 10.1161/JAHA.118.010321.


Acute Effects of Dietary Carbohydrate Restriction on Glycemia, Lipemia and Appetite Regulating Hormones in Normal-Weight to Obese Subjects.

Samkani A, Skytte MJ, Thomsen MN, Astrup A, Deacon CF, Holst JJ, Madsbad S, Rehfeld JF, Krarup T, Haugaard SB.

Nutrients. 2018 Sep 12;10(9). pii: E1285. doi: 10.3390/nu10091285.


Hyperosmolar Duodenal Saline Infusion Lowers Circulating Ghrelin and Stimulates Intestinal Hormone Release in Young Men.

Veedfald S, Wu T, Bound M, Grivell J, Hartmann B, Rehfeld JF, Deacon CF, Horowitz M, Holst JJ, Rayner CK.

J Clin Endocrinol Metab. 2018 Dec 1;103(12):4409-4418. doi: 10.1210/jc.2018-00699.


Acute administration of interleukin-6 does not increase secretion of glucagon-like peptide-1 in mice.

Christiansen CB, Lind SJ, Svendsen B, Balk-Møller E, Dahlby T, Kuhre RE, Hartmann B, Mandrup-Poulsen T, Deacon CF, Wewer Albrechtsen NJ, Holst JJ.

Physiol Rep. 2018 Jul;6(13):e13788. doi: 10.14814/phy2.13788.


Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas.

Kuhre RE, Wewer Albrechtsen NJ, Larsen O, Jepsen SL, Balk-Møller E, Andersen DB, Deacon CF, Schoonjans K, Reimann F, Gribble FM, Albrechtsen R, Hartmann B, Rosenkilde MM, Holst JJ.

Mol Metab. 2018 May;11:84-95. doi: 10.1016/j.molmet.2018.03.007. Epub 2018 Mar 17.


Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?

Andersen ES, Lund A, Bagger JI, Andreasen C, Grøndahl MF, Deacon CF, Hartmann B, Holst JJ, Knop FK, Vilsbøll T.

Diabetes Obes Metab. 2018 Aug;20(8):1937-1943. doi: 10.1111/dom.13321. Epub 2018 May 9.


A carbohydrate-reduced high-protein diet acutely decreases postprandial and diurnal glucose excursions in type 2 diabetes patients.

Samkani A, Skytte MJ, Kandel D, Kjaer S, Astrup A, Deacon CF, Holst JJ, Madsbad S, Rehfeld JF, Haugaard SB, Krarup T.

Br J Nutr. 2018 Apr;119(8):910-917. doi: 10.1017/S0007114518000521.


Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes.

Deacon CF.

Peptides. 2018 Feb;100:150-157. doi: 10.1016/j.peptides.2017.10.011. Review.


A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials.

Deacon CF.

Diabetes Obes Metab. 2018 Feb;20 Suppl 1:34-46. doi: 10.1111/dom.13135. Review.


Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production.

Wewer Albrechtsen NJ, Kuhre RE, Hornburg D, Jensen CZ, Hornum M, Dirksen C, Svane M, Gasbjerg LS, Jørgensen NB, Gabe MN, Balk-Møller E, Albrechtsen R, Winther-Sørensen M, Galsgaard KD, Meissner F, Jorsal T, Lund A, Vilsbøll T, Eliasen R, Bojsen-Møller KN, Idorn T, Deacon CF, Knop FK, Rosenkilde MM, Hartmann B, Feldt-Rasmussen B, Mann M, Madsbad S, Holst JJ.

Cell Rep. 2017 Nov 7;21(6):1452-1460. doi: 10.1016/j.celrep.2017.10.034.


Elevated Postoperative Endogenous GLP-1 Levels Mediate Effects of Roux-en-Y Gastric Bypass on Neural Responsivity to Food Cues.

Ten Kulve JS, Veltman DJ, Gerdes VEA, van Bloemendaal L, Barkhof F, Deacon CF, Holst JJ, Drent ML, Diamant M, IJzerman RG.

Diabetes Care. 2017 Nov;40(11):1522-1529. doi: 10.2337/dc16-2113.


Why is it so difficult to measure glucagon-like peptide-1 in a mouse?

Windeløv JA, Wewer Albrechtsen NJ, Kuhre RE, Jepsen SL, Hornburg D, Pedersen J, Jensen EP, Galsgaard KD, Winther-Sørensen M, Ørgaard A, Deacon CF, Mann M, Kissow H, Hartmann B, Holst JJ.

Diabetologia. 2017 Oct;60(10):2066-2075. doi: 10.1007/s00125-017-4347-7. Epub 2017 Jul 1.


Do we know the true mechanism of action of the DPP-4 inhibitors?

Andersen ES, Deacon CF, Holst JJ.

Diabetes Obes Metab. 2018 Jan;20(1):34-41. doi: 10.1111/dom.13018. Epub 2017 Jul 13. Review.


A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite.

Wewer Albrechtsen NJ, Asmar A, Jensen F, Törang S, Simonsen L, Kuhre RE, Asmar M, Veedfald S, Plamboeck A, Knop FK, Vilsbøll T, Madsbad S, Nauck MA, Deacon CF, Bülow J, Holst JJ, Hartmann B.

Am J Physiol Endocrinol Metab. 2017 Sep 1;313(3):E284-E291. doi: 10.1152/ajpendo.00005.2017. Epub 2017 Apr 18.


Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia.

Craig CM, Liu LF, Deacon CF, Holst JJ, McLaughlin TL.

Diabetologia. 2017 Mar;60(3):531-540. doi: 10.1007/s00125-016-4179-x. Epub 2016 Dec 14.


Glucagon-like Peptide 1 Receptor Signaling in Acinar Cells Causes Growth-Dependent Release of Pancreatic Enzymes.

Wewer Albrechtsen NJ, Albrechtsen R, Bremholm L, Svendsen B, Kuhre RE, Poulsen SS, Christiansen CB, Jensen EP, Janus C, Hilsted L, Deacon CF, Hartmann B, Holst JJ.

Cell Rep. 2016 Dec 13;17(11):2845-2856. doi: 10.1016/j.celrep.2016.11.051.


Pancreatic α-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation.

Larger E, Wewer Albrechtsen NJ, Hansen LH, Gelling RW, Capeau J, Deacon CF, Madsen OD, Yakushiji F, De Meyts P, Holst JJ, Nishimura E.

Endocrinol Diabetes Metab Case Rep. 2016;2016. pii: 16-0081. Epub 2016 Nov 21.


Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.

Nauck MA, Kahle M, Baranov O, Deacon CF, Holst JJ.

Diabetes Obes Metab. 2017 Feb;19(2):200-207. doi: 10.1111/dom.12802. Epub 2016 Nov 9.


Supplemental Content

Loading ...
Support Center